This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Go to paper
ABSTRACT:
The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.
Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:
- Management
- Policy
- Finance
- Law
- Regulation
- Bioethics
For more information, see the Journal of Commercial Biotechnology website
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Go to paper
ABSTRACT: The recent approval of a follow-on version of Pfizer's Genotropin (recombinant human growth hormone) signalled the beginning of the end of an era in which biopharmaceuticals enjoyed immunity from competition even after expiration of their patent protection. This paper describes many of the key scientific challenges facing the nascent ‘biogenerics’ industry and the evolving regulatory framework that will shape its competition with innovator companies...
The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.
Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:
- Management
- Policy
- Finance
- Law
- Regulation
- Bioethics
For more information, see the Journal of Commercial Biotechnology website
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirationsThis newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for December 17 2014 Instant Access to Deep Knowledge on Small-Molecule
DrugsSubscribers have
access to valuable datasets, including: - Patent litigation
- Clinical trial information
- International patent data
- Paragraph IV challenges
- Tentative approvals
- Drug Master Files
- Formulation
- Suppliers
- Dynamic search capabilities with data
export
- More…
More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents. |
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch database for
complete detailsDISCLAIMER:Although great care
is taken in the proper and correct provision of this service, thinkBiotech
LLC does not accept any responsibility for possible consequences of errors
or omissions in the provided information. There is no warranty that the
information contained herein is error free. Users of this service are
advised to seek professional advice and independent confirmation before
acting on any of the provided information. thinkBiotech LLC reserves the
right to amend, extend or withdraw any part or all of the offered service
without notice.
All trademarks and applicant names are the property
of their respective owners or licensors. 
